Mastering Pulmonology for FNP Boards: Essential Concepts You Can't Miss

Pulmonology · 6 min read · July 2, 2026

Mastering Pulmonology for FNP Boards: Essential Concepts You Can't Miss

Hey future FNPs! As you gear up for your board exams, you know that pulmonology is a significant and often challenging section. Respiratory conditions are common in primary care, and the boards will test your knowledge of diagnosis, management, and patient education. Don't let the thought of distinguishing between asthma and COPD or remembering pneumonia guidelines overwhelm you. We're going to break down the most critical pulmonology concepts you absolutely need to nail for your AANP and ANCC exams.

Let's dive in and build your confidence!

Asthma: The Reactive Airway

Asthma is a chronic inflammatory disease of the airways characterized by bronchial hyperresponsiveness and reversible airflow obstruction. It's crucial to understand the classification of asthma severity, as this dictates treatment.

Key Features:

Symptoms: Wheezing, coughing (especially nocturnal), chest tightness, shortness of breath. Symptoms are often worse at night or with exercise/triggers.
Diagnosis: Primarily clinical, supported by spirometry demonstrating reversible airflow obstruction (FEV1/FVC ratio < 0.70, with improvement of FEV1 by >12% and 200 mL after bronchodilator). A peak expiratory flow (PEF) meter is used for daily monitoring, not diagnosis.
Triggers: Allergens (dust mites, pollen, pet dander), irritants (smoke, pollution), exercise, cold air, respiratory infections, NSAIDs, GERD.

Management Principles:

Stepwise Approach: Treatment is based on severity, starting with intermittent and progressing to severe persistent.
- Intermittent: Symptoms ≤2 days/week, nighttime awakenings ≤2 times/month. Treatment: Short-acting beta-agonists (SABAs) PRN.
- Mild Persistent: Symptoms >2 days/week but not daily, nighttime awakenings 3-4 times/month. Treatment: Low-dose inhaled corticosteroids (ICS) daily + SABA PRN.
- Moderate Persistent: Daily symptoms, nighttime awakenings >1 time/week. Treatment: Low-dose ICS + long-acting beta-agonists (LABA) OR medium-dose ICS + SABA PRN.
- Severe Persistent: Throughout the day symptoms, nightly awakenings. Treatment: Medium-to-high dose ICS + LABA + SABA PRN. May consider oral corticosteroids.
Patient Education: Crucial for inhaler technique, trigger avoidance, and developing an Asthma Action Plan.

Clinical Pearl: Remember that SABAs are for rescue, and ICS are for control. If a patient is using their SABA more than twice a week (not for exercise-induced asthma), their asthma is not well-controlled, and their treatment plan needs to be stepped up.

COPD: The Irreversible Obstruction

Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent respiratory symptoms and airflow limitation that is not fully reversible. It encompasses emphysema (destruction of alveoli) and chronic bronchitis (chronic productive cough for at least 3 months in 2 consecutive years).

Key Features:

Risk Factors: Smoking is the overwhelming primary risk factor. Others include occupational dusts/chemicals, air pollution, and alpha-1 antitrypsin deficiency (rare, consider in young non-smokers).
Symptoms: Chronic cough, sputum production, dyspnea (worsens over time), wheezing. Often insidious onset.
Diagnosis: Confirmed by spirometry with a post-bronchodilator FEV1/FVC ratio < 0.70. Unlike asthma, the obstruction is largely irreversible.

Management Principles:

Smoking Cessation: The single most important intervention to slow disease progression.
Pharmacology:
- Bronchodilators: Form the cornerstone. Long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs) are preferred for maintenance. Short-acting versions (SAMAs, SABAs) are for rescue.
- Inhaled Corticosteroids (ICS): Added for patients with frequent exacerbations despite LABA/LAMA, often in combination with LABA.
- Oxygen Therapy: Indicated for chronic hypoxemia (PaO2 ≤ 55 mmHg or SaO2 ≤ 88%).
Non-Pharmacologic: Pulmonary rehabilitation, vaccinations (influenza, pneumococcal).

Board Tip: When differentiating asthma and COPD on boards, think reversibility (asthma) vs. irreversibility (COPD) on spirometry, and the typical age of onset (younger for asthma, older for COPD, especially with smoking history).

Pneumonia: Infection of the Lungs

Pneumonia is an acute infection of the lung parenchyma. FNPs frequently manage Community-Acquired Pneumonia (CAP).

Key Features:

Symptoms: Acute onset of cough (with or without sputum), fever, chills, dyspnea, pleuritic chest pain. Elderly patients may present with altered mental status or general weakness without classic respiratory symptoms.
Physical Exam: Tachypnea, crackles/rales, egophony, dullness to percussion.
Diagnosis: Primarily clinical, supported by chest X-ray (CXR) showing new infiltrates. Sputum cultures are generally not recommended for outpatient CAP.

Common Pathogens for CAP:

Typical: Streptococcus pneumoniae (most common), Haemophilus influenzae, Moraxella catarrhalis.
Atypical: Mycoplasma pneumoniae (walking pneumonia), Chlamydia pneumoniae, Legionella pneumophila.

Management Principles (Outpatient CAP for otherwise healthy adults):

First-line: Amoxicillin (high dose), Doxycycline, or a Macrolide (e.g., Azithromycin) if local macrolide resistance is <25%.
For patients with comorbidities or recent antibiotic use: Consider a respiratory fluoroquinolone (Levofloxacin, Moxifloxacin) or a beta-lactam + macrolide/doxycycline.
CURB-65 Score: Used to assess severity and guide admission decisions. (Confusion, Urea >7 mmol/L, Respiratory rate >30 breaths/min, Blood pressure <90/60 mmHg, Age ≥65). Score of 0-1 typically outpatient, 2 consider inpatient, ≥3 definitely inpatient.

Clinical Pearl: Always consider pneumococcal and influenza vaccinations for all patients, especially those with chronic respiratory conditions or those over 65, as a crucial preventive measure against pneumonia and its complications.

Tuberculosis (TB): The Stealthy Invader

TB is caused by Mycobacterium tuberculosis and primarily affects the lungs. It's essential for FNPs to understand screening, diagnosis, and treatment principles, especially given increasing global travel and immigration.

Key Features:

Transmission: Airborne droplets from active pulmonary TB patients.
Latent TB Infection (LTBI): No symptoms, non-infectious, positive TB test. Risk of progression to active TB.
Active TB Disease: Productive cough (>3 weeks), hemoptysis, fever, night sweats, weight loss, fatigue.
Screening:
- Tuberculin Skin Test (TST) / PPD: Measures induration (not erythema) at 48-72 hours. Interpretation varies based on risk factors.
- Interferon-Gamma Release Assays (IGRAs): (e.g., QuantiFERON-TB Gold, T-SPOT.TB) Blood tests, generally preferred in those who have received the BCG vaccine.
Diagnosis of Active TB: Positive sputum acid-fast bacilli (AFB) smear and culture (gold standard), positive nucleic acid amplification test (NAAT), and chest X-ray showing infiltrates, cavitations, or ghon complexes.

Management Principles:

LTBI Treatment: Short-course regimens are preferred (e.g., Isoniazid + Rifapentine weekly for 12 weeks, or Rifampin daily for 4 months). Longer courses of Isoniazid (6-9 months) are also options.
Active TB Treatment: Multi-drug regimen (typically 4 drugs: Isoniazid, Rifampin, Pyrazinamide, Ethambutol) for 6-9 months, directly observed therapy (DOT) is recommended.
Reporting: TB is a reportable disease to public health authorities.

Board Tip: Remember that a positive TST/IGRA only indicates exposure or latent infection. Active TB requires clinical symptoms, a positive sputum culture, and/or characteristic CXR findings. Never treat active TB with a single agent due to resistance risk.

Keep Breathing Easy on Your Boards!

Pulmonology might seem daunting, but by focusing on these high-yield topics and understanding the core differences and management principles, you'll be well-prepared. Break down each condition, understand the pathophysiology, diagnostic criteria, and treatment algorithms. You've got this! Keep practicing, stay confident, and remember that every question is an opportunity to show what you know.

Ready to solidify your knowledge and tackle more challenging questions? Visit store.thefnpreview.com for comprehensive board prep resources, including our QBank with thousands of practice questions designed to get you board-ready!